Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 202309 10 | Other Grant/Funding Number | Fundació La Marató 2022 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hospital Universitari de Bellvitge | OTHER |
| Fundació La Marató de TV3 | OTHER |
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to compare an integrated, multidisciplinar patient-centered CRP (Cardiac Rehabilitation Program) (intervention group) especially focused on covering the needs for the female and fragile population to the usual care conventional CRP (control group)
The Break-CR study is designed as an unicentric, open, randomized controlled trial, blind end-point evaluation and adjudication, to compare the feasibility, efficacy, and safety of a patient-centered CR-program versus usual care in patients after an acute coronary syndrome (ACS). The project aims to identify these barriers and design a CR-intervention to overcome said barriers and evaluate its usefulness in clinical practice.
The first part of this study consists of a qualitative study to specifically determine barriers, difficulties and facilitators that condition the participation of women in the CRPs, the second part of the study is undertaken to address the underrepresentation of women in CRPs and provide a solution to the recognized need to redesign CR programs to respond to the unique physiological and psychosocial needs of women. The aim is to design a groundbreaking intervention model that will respond to this need because it will incorporate all the factors on which a CR programme should be based, from a woman's perspective, from the beginning to the end, while also adressing the needs of the fragile portion ACS survivors.
It is hypothesized that the Break-CR program would be able to demonstrate greater improvements in incorporation and adherence of women and fragile patients to CR-programs, enhanced functional benefits, as well as improve patient-satisfaction and quality of life. Finally, the fundamental purpose is to enhance poor health outcomes of women and fragile patients with coronary diseases and to provide a solution that will contribute to bridge the health gap that exists in the field of cardiovascular diseases in health systems.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard of care | Active Comparator | Usual cardiac rehabilitation program |
|
| Personalized intervention program | Experimental | BREAK intervention group with more alternatives of aerobic and strength exercises and also offering remote options for fragile patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Personalised treatment | Behavioral | Patients going through a personalized intervention program |
|
| Measure | Description | Time Frame |
|---|---|---|
| Improvement in functional capacity | The primary endpoint of the study will be a composite functional capacity score, designed to capture the overall improvement in cardiorespiratory fitness following the rehabilitation intervention. This composite score will integrate the standardized change (from baseline to the end of the intervention) in the following four variables:
Each of these variables will be converted to z-scores based on the distribution of change scores in the study population. The composite score will be calculated as the mean of the four standardized values | First visit and 3 months after hospital discharge (after completing rehabilitation program) |
| Measure | Description | Time Frame |
|---|---|---|
| Physical Activity. IPAQ | Adherence to physical activity will be evaluated with the International Physical Activity Questionnaire (IPAQ). The IPAQ classifies individuals into three categories of physical activity level based on intensity, frequency, and total energy expenditure (measured in MET·minutes/week): Category 1: Low Physical Activity: The person does not meet the criteria for moderate or high physical activity. Considered sedentary or insufficiently active. Category 2: Moderate Physical Activity. A person meets any of the following:
Category 3: High Physical Activity. A person meets either:
|
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Cristina Enjuanes Grau, MD, PhD | Contact | +34 93 260 7078 | cenjuanes@bellvitgehospital.cat | |
| Pablo Morales, MD | Contact | +34 93 260 7078 | pmorales@idibell.cat |
| Name | Affiliation | Role |
|---|---|---|
| Cristina Enjuanes, MD, PhD | Institut d'Investigació Biomèdica de Bellvitge | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitari de Bellvitge | Recruiting | L'Hospitalet de Llobregat | Barcelona | 08907 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients will be recruited during 14 months, and will be followed for a fixed period of 6 months. The study protocol will be approved by the institutional review boards of the center (Bellvitge Biomedical Research Institute, IDIBELL).
The trial will be designed and implemented by the BREAK Steering Committee. Oversight of the study will be conducted by the Chair and the two Co-Chairs in liason with the BREAK Executive Committee. Safety will be reported by local investigators in accordance with the current legislation that regulates pharmacovigilance in Spain.
End-point evaluation of the primary outcome will be performed by an independent end-point committee blinded to the group allocation of patients.
Not provided
Not provided
Not provided
| Usual Care | Other | Usual cardiac rehabilitation program |
|
| First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge |
| Physical Activity. Podometer | According to pedometer readings which will be given to patients (steps/day), physical activity is categorized as follows: Sedentary or inactive < 5,000 steps/day Low active 5,000-9,999 steps/day Active 10,000-12,499 steps/day Very active ≥ 12,500 steps/day | First visit; 3 months (after completing rehabilitation program) and 6 months after hospital dischargeFirst visit and 6 months after hospital discharge |
| Psychological status | Psychological status will be evaluated for screening of anxiety and depression (PHQ-9 and GAD-7 scales). The PHQ-9 is a 9-item questionnaire used to screen for depression. Each item is scored from 0 (not at all) to 3 (nearly every day), with a total score range of 0-27. Cut-off points: 5-9: mild depression 10-14: moderate depression 15-19: moderately severe depression 20-27: severe depression The GAD-7 is a 7-item scale assessing generalized anxiety. Each item is scored 0-3 (same as PHQ-9), total score range: 0-21. Cut-off points: 5-9: mild anxiety 10-14: moderate anxiety 15-21: severe anxiety A score ≥10 on either scale suggests clinically relevant symptoms, warranting further evaluation. | First visit; 3 months (after completing rehabilitation program) and 6 months after hospital dischargeFirst Visit and 6 months after hospital discharge |
| Dietary Changes | ChatGPT Plus To assess dietary changes, we will use two validated tools: the DEBQ (Dutch Eating Behavior Questionnaire) and the PREDIMED Mediterranean Diet questionnaire. The DEBQ evaluates emotional, external, and restrained eating behaviors using 33 items rated on a 5-point scale (from "never" to "very often"). It helps identify if a patient eats more in response to emotions, sensory cues, or dieting efforts. Higher scores in each subscale indicate a stronger influence of that behavior on eating patterns. The PREDIMED questionnaire has 14 questions and measures adherence to the Mediterranean diet. Each healthy habit (e.g., using olive oil, eating fruits/vegetables, low processed food intake) scores 1 point. Scores ≥9 = good adherence, <9 = low adherence. These tools allow monitoring of diet quality and behavior-related eating changes | In-hospital evaluation and 6 months after hospital discharge |
| Body composition | Nutritional status will be evaluated with the use of bioimpedanciometry (BIA), monitoring changes in body composition such as % of muscle and fat mass. | First visit and 3 months after hospital discharge (after completing rehabilitation program) |
| Sarcopenia | Sarcopenia will be assessed in patients using handgrip dynamometry, expressed in kilograms (kg). Handgrip strength (HGS) is a validated proxy for overall muscle strength and is widely used in clinical settings for sarcopenia screening. According to the international norms published by Tomkinson et al. (2025), cut-off values will be based on sex- and age-specific percentiles. Patients with HGS values below the 20th percentile for their age and sex will be considered at risk of sarcopenia. This threshold aligns with evidence suggesting that the lowest quintile is predictive of poorer health outcomes and increased mortality. These percentiles provide a robust, standardized reference to guide early intervention. | First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge |
| Frailty | Frailty will be assessed using the Short Physical Performance Battery (SPPB), a validated tool that evaluates lower extremity function through three components: Balance (side-by-side, semi-tandem, tandem stand) Gait speed (usual pace over 4 meters) Chair stands (time to rise from a chair five times) Each component is scored from 0 to 4, giving a total score range of 0 to 12 (higher scores = better function). Cut-off points for frailty classification: 0-6 points: frail 7-9 points: pre-frail 10-12 points: robust This tool helps identify patients at risk of mobility disability and adverse outcomes and is recommended for use in both research and clinical practice. | First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge |
| Patient reported quality of life | Changes in quality of life will be assessed using two validated instruments: the EuroQol-5D (EQ-5D) and the HeartQoL (HRQoL) questionnaire. (EQ-5D) This tool evaluates health across 5 dimensions: Mobility Self-care Usual activities Pain/discomfort Anxiety/depression Each dimension has 3 levels: no problems, some problems, and extreme problems. It also includes a visual analogue scale (VAS) from 0 (worst imaginable health) to 100 (best imaginable health), allowing patients to rate their overall health state. Higher scores indicate better perceived health. HRQoL The HRQoL is a disease-specific questionnaire for patients with ischemic heart disease. It has 14 items divided into two dimensions: Physical (10 items) Emotional (4 items) Each item is scored from 0 (worst HRQoL) to 3 (best HRQoL). Scores are averaged for each subscale and the global score; higher scores reflect better quality of life. Changes over time can reflect improvements or deterioration in health perception | First visit and 3 months after hospital discharge (after completing rehabilitation program) |
| Sleep quality | Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a standardized questionnaire that evaluates sleep patterns over the past month. The PSQI consists of 19 self-rated items grouped into 7 components: Subjective sleep quality Sleep latency Sleep duration Habitual sleep efficiency Sleep disturbances Use of sleeping medication Daytime dysfunction Each component is scored from 0 to 3, producing a global score ranging from 0 to 21. Scores ≤5: good sleep quality Scores >5: poor sleep quality Higher scores reflect worse sleep quality. The PSQI is widely used in both research and clinical practice to monitor sleep-related changes and identify individuals with potential sleep disorders. | First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge |
| Sexual dysfunction | Sexual dysfunction will be assessed using validated, sex-specific questionnaires: For men: IIEF (International Index of Erectile Function) The IIEF evaluates male sexual function over the past 4 weeks using 15 items distributed across 5 domains: Erectile function (items 1-5, 15) Orgasmic function (items 9-10) Sexual desire (items 11-12) Intercourse satisfaction (items 6-8) Overall satisfaction (items 13-14) Each item is scored from 0 or 1 to 5, with higher scores indicating better sexual function. Erectile dysfunction is usually classified as: 1-10: severe 11-16: moderate 17-25: mild to moderate 26-30: normal For women: FSM (Female Sexual Function Questionnaire) This tool consists of 19 items grouped into 6 domains: Desire (items 1-2) Arousal (items 3-6) Lubrication (items 7-10) Orgasm (items 11-13) Satisfaction (items 14-16) Pain (items 17-19) Some items are reverse-scored (8, 10, 12, 17-19). Higher total and subscale scores indicate better sexual function. | First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge |
| Readmission and mortality rates | Readmission Rate (All-Cause and Cardiovascular) Patient outcomes will include evaluation of hospital readmissions, classified as: All-cause readmissions: any reason for hospital admission after discharge. Cardiovascular readmissions: admissions due to heart-related conditions (e.g., heart failure, myocardial infarction, arrhythmia). We will register both the rate (percentage of patients readmitted) and the total number of readmissions. A lower readmission rate reflects better clinical stability and care continuity. Mortality (All-Cause and Cardiovascular) Mortality will be monitored and classified into: All-cause mortality: death from any origin. Cardiovascular mortality: death due to cardiac or vascular causes (e.g., sudden cardiac death, stroke, heart failure). These indicators will evaluate patient prognosis and treatment effectiveness over the follow-up period. | First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge |
| Adherence to program | Patient adherence and retention will be evaluated as follows: 1.1 Adherence analysis: the total percentage of exercise sessions attended in both groups (conventional vs domiciliary program). And also adherence to the different types of sessions (respiratory, relaxation, aerobic and strength) 1.2. Retention rate: the number of participants who finish the training divided by the number of randomized patients. | First visit; 3 months after discharge (after completing rehabilitation program) |
| Patient experience | Patient's experience with both the cardiac rehabilitation program and the use of technology will be assessed using a LIKERT scale (1 Not at all to 5 A lot) asking the following questions:
The results will be analyzed before starting the program and at the end to determine if patient's impression has changed. | First visit; 3 months (after completing rehabilitation program) and 6 months after hospital discharge |
| ID | Term |
|---|---|
| D054058 | Acute Coronary Syndrome |
| D000073496 | Frailty |
| D055948 | Sarcopenia |
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D012816 | Signs and Symptoms |
| D003327 | Coronary Disease |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
Not provided
Not provided